Recent advances in AI applications are reshaping biotech research and development. Researchers at NIH introduced GeneAgent, an AI agent that improves accuracy of gene-set analysis by reducing hallucinations via database cross-checking. Separately, Stanford developed 'virtual scientist' AI labs to accelerate hypothesis generation and problem-solving in biology. Pharma leaders like Sanofi’s CEO also advocate for integrating AI in drug development decision-making processes, emphasizing AI’s impartiality and efficiency. These developments highlight AI’s growing role in expediting discovery and optimizing research pipelines in biotechnology.